Using a rodent model of chronic adriamycin (ADR) also called doxorubicin hydrochloride treatment, Allen et al. 2019, tested two strategies (1) microglia depletion with the CSF1R (colony stimulating factor-1 receptor) inhibitor PLX5622 and (2) treatment with iMG (human induced pluripotent stem cell-derived microglia)-derived extracellular vesicles (EVs) and checked the alteration in cognitive impairment [104]. The gene discussed is CSF1R; the disease is Cognitive impairment.